The study evaluated 73 patients (120 eyes) with mild, moderate, and severe glaucoma, each completing both examinations during the same visit. Researchers compared global indices (mean sensitivity and mean defect), pointwise sensitivity, total deviation, test duration, reliability metrics, and patient comfort.
Key findings
- Excellent agreement between VisionOne™ and the Octopus 900 across all stages of glaucoma.
- Excellent correlation for the global indices mean sensitivity and mean defect (ρ = 0.97, p < 0.0001).
- Strong spatial correlation for pointwise sensitivity and total deviation (ρ = 0.88–0.89).
- Agreement remained consistently high even in advanced glaucoma, a patient population that has been largely underrepresented in previous VR perimeter studies.
- Comparable examination times (6.3 vs. 6.5 minutes).
- Equivalent reliability indices.
- No patient discontinuing the examination.
Clinical significance: addressing the limitation of VR perimetry
This independent validation from University Hospital Bern represents a major milestone for PeriVision and VisionOne™. As Dr. Serife Kucur, CTO & co-founder of PeriVision, explains: “One of the main concerns surrounding virtual reality perimetry has been its limited ability to accurately assess patients with advanced glaucoma. This study directly addresses that question: we demonstrated that VisionOne™ maintains excellent agreement with the gold standard across the entire disease spectrum, including advanced cases.”
By combining:
- clinical performance equivalent to gold-standard stationary perimeters,
- a high degree of automation,
- a compact footprint,
- an intuitive user interface, and
- outstanding workflow efficiency,
VisionOne™ offers a compelling next-generation alternative to conventional automated perimetry for routine clinical practice.
